Macrogen, Inc. (KOSDAQ:038290)
11,250
+220 (1.99%)
Jul 21, 2026, 3:30 PM KST
Macrogen Revenue
Macrogen had revenue of 45.29B KRW in the quarter ending March 31, 2026, with 10.57% growth. This brings the company's revenue in the last twelve months to 199.60B, up 37.56% year-over-year. In the year 2025, Macrogen had annual revenue of 195.27B with 43.82% growth.
Revenue (ttm)
199.60B
Revenue Growth
+37.56%
P/S Ratio
0.60
Revenue / Employee
409.85M
Employees
487
Market Cap
119.58B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 195.27B | 59.49B | 43.82% |
| Dec 31, 2024 | 135.78B | 2.97B | 2.24% |
| Dec 31, 2023 | 132.80B | -5.81B | -4.19% |
| Dec 31, 2022 | 138.62B | 9.44B | 7.31% |
| Dec 31, 2021 | 129.17B | 16.57B | 14.72% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bioneer | 338.01B |
| GC Cell | 163.35B |
| JETEMA, | 77.07B |
| HLB Therapeutics | 67.56B |
| Amicogen | 43.44B |
| Anterogen.Co.,Ltd. | 8.06B |
| Genexine | 5.81B |
| MedPacto | 4.79B |